Differential epithelial expression of the putative innate immune molecule SPLUNC1 in Cystic Fibrosis
© Bingle et al. 2007
Received: 09 May 2007
Accepted: 07 November 2007
Published: 07 November 2007
Skip to main content
© Bingle et al. 2007
Received: 09 May 2007
Accepted: 07 November 2007
Published: 07 November 2007
Short PLUNC1 (SPLUNC1) is the founding member of a family of proteins (PLUNCS) expressed in the upper respiratory tract and oral cavity, which may function in host defence. It is one of the most highly expressed genes in the upper airways and the protein has been detected in sputum and nasal secretions. The biology of the PLUNC family is poorly understood but in keeping with the putative function of the protein as an immune defence protein, a number of RNA and protein studies have indicated that SPLUNC1 is increased in inflammatory/infectious conditions such as Cystic Fibrosis (CF), COPD and allergic rhinitis.
We used immunohistochemistry to localise SPLUNC1 in lung tissue from patients with CF and a range of other lung diseases. We used a range of additional markers for distinct cell types to try to establish the exact site of secretion of SPLUNC1. We have complemented these studies with a molecular analysis of SPLUNC1 gene expression in primary human lung cell cultures and isolated inflammatory cell populations.
In CF, expression of SPLUNC1 is significantly elevated in diseased airways and positive staining was noted in some of the inflammatory infiltrates. The epithelium of small airways of CF lung exhibit significantly increased SPLUNC1 staining compared to similar sized airways in non-CF lungs where staining is absent. Strong staining was also seen in mucous plugs in the airways, these included many inflammatory cells. No alveolar epithelial staining was noted in CF tissue. Airway epithelial staining did not co-localise with MUC5AC suggesting that the protein was not produced by goblet cells. Using serial sections stained with neutrophil elastase and CD68 we could not demonstrate co-localisation of SPLUNC1 with either neutrophils or macrophages/monocytes, indicating that these cells were not a source of SPLUNC1 in the airways of CF lungs. No change in staining pattern was noted in the small airways or lung parenchyma of other lung diseases studied including, COPD, emphysema or pneumonia where significant NE and CD68 staining was noted. Cultures of primary tracheobronchial epithelial cells were analysed by RT-PCR and showed that pro-inflammatory mediators did not induce expression of SPLUNC1. We have also shown that SPLUNC1 gene expression was not seen in isolated human mononuclear cells, macrophages or neutrophils.
These studies show that SPLUNC1 is specifically and significantly increased in the small airways of lungs from patients with CF. They further suggest that it is the airway epithelium that is responsible for the increased levels of SPLUNC1 in CF and not inflammatory cells; this could be a defensive response to the infectious component of the disease.
SPLUNC1 is the founder member of the PLUNC family of putative innate immune molecules, and is highly expressed in the epithelium of the upper respiratory tract, nasopharynx and submucosal glands . The mouse orthologue of SPLUNC1, Palate Lung Nasal Clone (plunc) was first identified as a molecule expressed in the developing mouse oral cavity around the time of palatal shelf closure; it is expressed in the nasal epithelium of the mouse embryo and the trachea and bronchi of adult mouse lung . Using a systematic, bioinformatic and expression study we subsequently identified the wider PLUNC family of nine human genes located on chromosome 20 [3, 4]. PLUNC genes are expressed in overlapping patterns predominantly in the upper respiratory tract, nasal passages and oral cavity [1, 3]. All PLUNC proteins contain signal peptides suggesting they would be secreted into the extracellular fluids bathing these locations. Due to the structural similarity between PLUNCs and the lipid/LPS binding, innate defence proteins lipopolysaccharide binding protein (LBP) and Bactericidal/permeability-increasing protein (BPI), we, and others, have hypothesised that PLUNCs may function in the innate immune defence of the respiratory tract. [3–7]. However, direct proof of such a host defence function remains to be published. SPLUNC1 mRNA has been identified in tracheal epithelium [8, 9] and in sub-mucosal glands and ducts . The protein was localised to the same sites , and our previous studies have shown that the submucosal glands of the upper respiratory tract and the minor mucosal glands of the oropharynx appear to be the major sites of protein localisation . These same studies also show that expression of SPLUNC1 is limited to a few non-ciliated epithelial cells of the upper airways and is absent from small airways and from peripheral lung . This contrasts to the situation in the mouse where in situ hybridisation suggests that splunc1 is expressed in the majority of epithelial cells in the trachea and main bronchi [1, 8]. SPLUNC1 is one of the major proteins secreted from differentiated human tracheo-bronchial epithelial cells in culture  and has been identified as a highly expressed gene in such cells in a number of studies [12, 13].
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations of the CF trans-membrane regulator (CFTR) gene [14, 15]. The genetic defect in CF leads to abnormal epithelial chloride and water transport and this results in increased viscosity of, and subsequent decreased clearance of, airway secretions. This in turn affects airway defence resulting in chronic lung infection . Inflammatory cells recruited in response to this active infection lead to a state of chronic airway inflammation. CF lung disease is therefore characterised by plugging of airways associated with persistent bacterial infection and massive neutrophil infiltration . The CF lung becomes infected with a distinctive bacterial flora, including Pseudomonas aeruginosa, Staphylococcus aureus, and organisms of the Burkholderia cepacia complex which are associated with plugging of the small airways. This plugging directly contributes to the impaired lung function seen in CF, leading to respiratory failure. CF lung disease is largely restricted to the airway compartment of the lung with the parenchyma being largely unaffected. There is no effective treatment for CF and patients with the disease will ultimately require lung transplantation . Innate immune defences of the lung are significantly impaired in CF as a consequence of a combination of factors, including phenotypic alterations of the airway epithelium, the elevated viscosity, alterations in the ionic strength and pH of the airway lining fluid and the increased levels of inflammatory cells present in the inflamed tissues . The defects in innate defences become self-sustaining, because the inflammatory cell derived proteases, including neutrophil elastase (NE), released from the abundant mass of recruited cells, specifically degrade many host defence proteins .
As a putative innate defence molecule expressed in the upper airways and in submucosal glands, SPLUNC1 could potentially be involved in combating the chronic infections seen in CF and other lung diseases with an infectious component. Previous studies have shown that SPLUNC1 is elevated in the sputum of patients with COPD . Although similar studies have not been shown in CF, a proteomic study has shown that CF nasal epithelial cells contain increased levels of SPLUNC1  and molecular studies have shown that CF epithelial cells appear to express abundant SPLUNC1 . In this paper we demonstrate that CF airways specifically express abundant SPLUNC1 and show that this elevated protein expression is not the product of the inflammatory cells that accumulate in the disease.
The tissue used in this study was collected with ethical approval only on a fully anonymised basis and thus we have no further patient details. Serial sections were cut from formalin-fixed and paraffin-embedded tissue as described . For normal tissues, sections were taken so as to be as representative of normal architecture as possible, although as all tissues were removed for medical reasons there was some evidence of disease in some sections. Sections from the major bronchi and peripheral lung were cut from 10 cases of normal lung and similar samples were also obtained from 10 patients with CF who were undergoing lung transplantation. We also studied 10 cases from patients with emphysema and two cases from patients with pneumonia. The histologically "normal" and emphysematous samples were resections taken during surgery for cancer, where no tumour tissue was seen to be present, the CF tissue was removed during the course of transplantation and the pneumonia tissue was collected during post-mortem. The slides were treated with 2% hydrogen peroxide in methanol for 20 minutes to quench endogenous peroxidase.
The following antibodies were used in this study: A polyclonal antibody raised against human SPLUNC1  (final dilution 1:300); a polyclonal antibody to human mucin 5AC (MUC5AC, a gift from David Thornton, University of Manchester, UK; final dilution 1:250); monoclonal antibodies to tryptase, CD68 and neutrophil elastase purchased from Dako (1:1200, 1:400 and 1:300 respectively). A standard antigen retrieval procedure using tri-sodium citrate in a microwave for 8 minutes was used for the MUC5AC, tryptase and CD68 antibodies. The specificity of the SPLUNC1 antibody has previously been shown by western blotting using a number of recombinant PLUNC proteins . Sections were incubated with 100% normal serum (goat for polyclonal antibodies, horse for monoclonal antibodies) at room temperature for 30 minutes and then at 4°C overnight with the antibodies diluted as indicated above with 100% normal serum. Rabbit or mouse IgG (DAKO) was used as a negative controls on replicate slides. A Vectastain Elite ABC kit (Vector Laboratories) containing an appropriate biotin-labelled secondary antibody was used according to the manufacturer's instructions. Peroxidase enzymatic development was performed using, a Vector NovaRed substrate kit resulting in red staining in positive cells. Sections were counterstained with haematoxylin, dehydrated to xylene and mounted in DPX.
Human tracheobronchial epithelial (TBE) cell cultures were prepared by methods described previously  using trachea and bronchi from lungs that were not deemed suitable for transplant through the Life Alliance Organ Recovery Agency of the University of Miami and approved by the local institutional review board. Cells were grown in a medium containing 50% DMEM and 50% LHC basal medium (Biosource International, Camarillo, CA, USA) supplemented with hormones and trace elements as described . Upon reaching confluence (after 3–7 d), the medium from the apical surface was removed, leaving the top surface exposed to air (air-liquid interface cultures, ALI). To study the effect of retinoic acid (RA) on the expression of SPLUNC1, normal RA (50 nM) was removed from the medium of fully differentiated TBE cells after 14 days exposed to air. To study the effects of pro-inflammatory mediators on SPLUNC1 gene expression, TBE cells were stimulated with 25 ng/ml of IL-1β or TNFα (both from R & D Systems, Inc, Minneapolis, MN, USA) for 6, 24 or 48 hours prior to harvest. Stimulations for RNA analysis were performed on cultures from three individual donors.
Human peripheral blood neutrophils, mononuclear (MNC) cells, monocytes and T and B cell enriched cell populations from normal healthy donors, were isolated by density gradient centrifugation and cultured as previously described . Monocyte-derived macrophages were differentiated from monocytes on tissue culture plastic using standard protocols . A SPLUNC1 expressing CHO cell line was generated from a full-length human SPLUNC1 expression clone  using the Flp-in system (Invitrogen).
Total RNA was isolated as previously described . Reverse transcription was also performed as previously described  in a total volume of 25 μl using an oligo-dT primer and 1 μg of total RNA. PCR reactions were performed using 1 μl of each reaction product and the following primer pairs. SPLUNC1F 5' ATG CCC TCA GCA ATG GCC TGC T 3', SPLUNC1R 5' GTG AGG CTG TCC AGA AGA CC 3': WFDC2 F: 5' CGG CTT CAC CCT AGT CTC AG 3'; WFDC2 R: 5' AAA GGG AGA AGC TGT GGT CA 3'; Elafin F: 5' ACC TTC CTG ACA CCA TGA GG 3'; Elafin R: 5' GAT GAG AGA GGC AGC TCC AG 3'; BCL2A1 F 5' GCC ACC ATG ACA GAC TGT GAA TTT GGA TAT 3', BCL2A1R 5' TCA ACA GTA TTG CTT CAG GAG AGA 3': Primer pairs were designed using Primer3  and were designed to cross intro/exon boundaries. 30 cycles of the following program (94°C for 1', 60°C for 2' and 72°C for 3') generated the appropriately sized products, which were resolved on 2% TAE agarose gels, stained with ethidium bromide and photographed. Representative samples of each were directly cloned in TOPO pCRII (Invitrogen) and sequenced.
Since our original description of the expression pattern of human SPLUNC1 gene being limited to the upper respiratory tract  a number of other expression studies have shown that it is highly expressed in the tracheobronchial epithelium of the human respiratory tract. A number of proteomic and protein studies have shown that the protein can be detected in nasal secretions [29–32] where levels may be altered by chemical injury [29, 30] and viral infection ; it has also been studied in sputum, where levels appear to be increased in COPD . A large-scale EST sequencing and characterisation study appeared to show that the SPLUNC1 gene was more highly expressed in airway epithelial cells from CF patients compared to non-CF patients . Additionally, CF nasal epithelial cells have also been shown to contain increased levels of SPLUNC1 compared to normals .
More recently we performed an extensive study of the localisation of SPLUNC1 protein in normal human tissues from the respiratory tract, oral cavity and nasopharynx . These studies confirmed previous findings that the gene was expressed in submucosal glands and some cells of the tracheal epithelium but extended our observations to show that the protein was expressed in multiple minor mucosal glands from the nasal antrum and throughout the oral cavity including glands localised in the tongue and adjacent to tonsils. This study also showed that small airways, that is those which contain neither cartilage nor submucosal glands and peripheral lung tissue, do not express SPLUNC1 . In striking contrast to the situation described for normal lung, our present study has clearly shown that SPLUNC1 is significantly increased in the small airways of patients with advanced CF. The specificity of this observation is shown by the fact that similar alterations are not seen in patients with other lung conditions, including bacterial pneumonia and emphysema, as well as tuberculosis (results not shown). It is also noteworthy that this change in abundance of SPLUNC1 in CF is found at sites where the protein is not normally seen. Our studies suggest that this is likely due to an increase in epithelial production of the protein as we have been unable to show that SPLUNC1 is present in the inflammatory cells that accumulate within the diseased airways in this condition. Indeed no SPLUNC1 staining is seen in the peripheral lung tissue of the same CF patients nor in the peripheral lung of patients with bacterial pneumonia, both of which contain significant numbers of neutrophils, monocytes and macrophages. We were also unable to show that SPLUNC1 mRNA was present in isolated human neutrophils, monocytes or monocyte-derived macrophages. As the transcription of many neutrophil gene products is largely restricted to the period in which the cells are developing within the bone marrow [27, 33] we also looked at expression in highly purified cell populations from this source. Again, these samples were negative for SPLUNC1 mRNA. On the basis of these observations we suggest that SPLUNC1 is not a significant product of inflammatory cells in the diseased airway.
We have been also been unable to show that treatment of airway cells with the classical inflammatory mediators, IL-1β and TNFα (nor indeed bacterial LPS or hNE) affects SPLUNC1 gene expression suggesting that the gene is not transcriptionally regulated by these factors. This is consistent with a recent report showing a similar lack of induction of the SPLUNC1 in nasal epithelial cell cultures treated with the same stimuli . On the basis of these results we would suggest that the increased SPLUNC1 that is seen in the epithelial cells of the CF airways is the result of a phenotypic alteration in the epithelium itself. It is well known that airway epithelial phenotypic changes are associated with changes in gene expression and this has been well studied in tissue culture models. Our data show that SPLUNC1 gene expression in airway epithelium in culture requires a continued exposure to RA as this maintains a mucociliary phenotype. This observation is consistent with other published data [9, 10], including the study of Ross et al, that shows that SPLUNC1 is one of the most differentially expressed genes during this differentiation process . In our cultures we have shown that SPLUNC1 is present in non-ciliated cells (results not shown) but in vivo it is clear that the protein is only expressed in a limited number of epithelial cells  and is not located in goblet cells.
Two significant questions arise from our observations. Firstly, what is the consequence of this alteration in SPLUNC1 production in CF and secondly, are levels of SPLUNC1 increased in less severe CF lung disease? In line with the hypothesised function of SPLUNC1 as an innate immune defence protein, it might be expected that the protein would be increased as a defensive response in severe CF where the pathogenic load is markedly elevated. It is clear that other innate defence factors are also increased in this condition but perhaps the severity of the inflammatory disease coupled with the significant pathogenic load overcomes the defensive capability of the innate immune shield. One of the major limitations of this study is that we have only been able to obtain tissue from patients with severe CF at the time of lung transplantation. It remains to be seen if similar alterations in SPLUNC1 localisation and expression are found in less severe cases; this could be accomplished in future studies by examining levels of SPLUNC1 protein in CF secretions.
These studies show that the putative innate immune molecule, SPLUNC1 is specifically and significantly increased in the small airways of lungs from patients with CF. They further suggest that it is the airway epithelium that is responsible for the increased levels of SPLUNC1 in CF and not inflammatory cells; this could be a defensive response to the infectious component of the disease.
Bactericidal Permeability Increasing Protein
Chinese Hamster Ovary
Chronic Obstructive Pulmonary Disease
Lipopolysaccharide Binding Protein
Palate Lung Nasal Clone
Short PLUNC 1
Tumour Necrosis Factor α
This work was funded by the British Lung Foundation and the Wellcome Trust. We thank Dr Helen Marriott for the MDM RNA samples and Dr Jack Cowland for analysis of SPLUNC1 expression in neutrophil precursor array data sets.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.